Michael A. Morse

3.0k citations

24 papers · 2.1k indexed · 2 hit papers · h-index 13

Oncology top 1%
- Cancer Immunotherapy and Biomarkers 8
- Colorectal Cancer Treatments and Studies 7
- CAR-T cell therapy research 5
- Pancreatic and Hepatic Oncology Research 4
- Cancer Treatment and Pharmacology 3
- Lung Cancer Research Studies 3
Pathology and Forensic Medicine top 2%
- Genetic factors in colorectal cancer 5
Cancer Research top 5%
Immunology top 5%
- Immunotherapy and Immune Responses 3
Hepatology top 5%

Co-authors: Michael J. Overman Fabio Gelsomino Ka Yeung Mark Wong Bart Neyns Thierry André Sara Lonardi Andrew Hill Scott Kopetz
Cited by: Oncology Pathology and Forensic Medicine Cancer Research
Partner nations: United States Belgium France

In The Last Decade

Michael A. Morse

21 papers receiving 2.1k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2022 Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142
2018 Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

Peers

Countries citing papers authored by Michael A. Morse

Since Specialization

Citations

This map shows the geographic impact of Michael A. Morse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael A. Morse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael A. Morse more than expected).

Fields of papers citing papers by Michael A. Morse

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael A. Morse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael A. Morse. The network helps show where Michael A. Morse may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Michael A. Morse, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael A. Morse Line = papers co-authored together Michael A. Morse links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Hemodynamics and Mid-Term Clinical Outcomes Following Valve-in-Valve TAVR With Balloon-Expandable Valves Amr Abbas,Tsuyoshi Kaneko,Houman Khalili,S R Kapadia,Vasilis C Babaliaros,Adam B Greenbaum,Thomas A. Schwann,Pradeep Yadav,Issam D Moussa,Grant W Reed,Roger J Laham,Michael A. Morse,Pedro Villablanca,Evelio Rodríguez,Jeremiah P Depta,James M. McCabe,V. Bapat,Vinod H Thourani,Amar Krishnaswamy	2026	0
2	Residual Mitral Regurgitation Interacts With Transmitral Mean Pressure Gradient to Modify the Association With Mortality Following Transcatheter Edge-to-Edge Repair Neal Duggal,Milo Engoren,Paul Sorajja,D. Scott Lim,Jason H. Rogers,Scott Chadderdon,Firas Zahr,Evelio Rodríguez,Michael A. Morse,Enrique Garcia‐Sayan,Nishtha Sodhi,Marcella Calfon Press,Gorav Ailawadi	2025	0
3	Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142breakdown → Thierry André,Sara Lonardi,Ka Yeung Mark Wong,H.J. Lenz,Fabio Gelsomino,Massimo Aglietta,Michael A. Morse,Eric Van Cutsem,Ray McDermott,Andrew Hill,Michael B. Sawyer,Alain Hendlisz,Bart Neyns,Sandzhar Abdullaev,Arteid Memaj,Ming Lei,Michael F. Dixon,Scott Kopetz,Michael J. Overman	2022	154
4	Expression of X-Linked Inhibitor of Apoptosis Protein (XIAP) in Breast Cancer Is Associated with Shorter Survival and Resistance to Chemotherapy Gayathri R. Devi,Pascal Finetti,Michael A. Morse,Seayoung Lee,Alexandre de Nonneville,Steven Van Laere,Jesse D. Troy,Joseph Geradts,Shannon J. McCall,François Bertucci	2021	22
5	Long Term Survival Following DeltaRex-G/DeltaVax Tumor-Targeted Gene Therapy for Advanced Chemotherapy-Resistant Malignancies: An Academic Milestone Seiya Liu,Sant P. Chawla,Howard W. Bruckner,Michael A. Morse,Noah Federman,Amor M. Srikureja,Don Arlen Brigham,Jorge Ignacio,Filomena San Juan,Roseo A Manalo,Erlinda M. Gordon	2021	3
6	A case report of microsatellite instability (MSI)-high, HER2 amplified pancreatic adenocarcinoma with central nervous system metastasis Nicholas C. DeVito,Colm Kelleher,Kyle C. Strickland,James L. Abbruzzese,Carey K. Anders,Brent A. Hanks,Jingquan Jia,Niharika B. Mettu,Michael A. Morse,Margot O’Neill,Hope E. Uronis,S. Yousuf Zafar,John H. Strickler	2021	1
7	A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer John H. Strickler,Christel Rushing,Donna Niedzwiecki,Abigail McLeod,Ivy Altomare,Hope E. Uronis,Shiaowen David Hsu,S. Yousuf Zafar,Michael A. Morse,David Chang,James L. Wells,Kimberly Blackwell,P. Kelly Marcom,Christy Arrowood,Emily Bolch,Sherri Haley,Fatima Rangwala,Ace J. Hatch,Andrew B. Nixon,Herbert I. Hurwitz	2019	9
8	Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer Michael A. Morse,Michael J. Overman,Leighanne Hartman,Taline Khoukaz,Edith Brutcher,Heinz‐Josef Lenz,Ajlan Atasoy,Tong Shangguan,Huanyu Zhao,Bassel F. El‐Rayes	2019	77
9	Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancerbreakdown → Michael J. Overman,Sara Lonardi,Ka Yeung Mark Wong,Heinz‐Josef Lenz,Fabio Gelsomino,Massimo Aglietta,Michael A. Morse,Eric Van Cutsem,Ray McDermott,Andrew Hill,Michael B. Sawyer,Alain Hendlisz,Bart Neyns,Magali Svrcek,Rebecca A. Moss,Jean-Marie Ledeine,Z. Alexander Cao,Shital Kamble,Scott Kopetz,Thierry André	2018	1429
10	Whole Recombinant Saccharomyces cerevisiae Yeast Expressing Ras Mutations as Treatment for Patients With Solid Tumors Bearing Ras Mutations: Results From a Phase 1 Trial Allen Lee Cohn,Michael A. Morse,Bert H. O’Neil,Samuel H. Whiting,Claire Coeshott,John A. Ferraro,Donald Bellgrau,David Apelian,Timothy C. Rodell	2018	32
11	Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry Brendan D. Curti,Gregory A. Daniels,David F. McDermott,Joseph I. Clark,Howard L. Kaufman,Theodore F. Logan,Jatinder Singh,Meenu Kaur,Theresa L. Luna,Nancy Gregory,Michael A. Morse,Michael K. Wong,Janice P. Dutcher	2017	27
12	Percutaneous biliary drainage catheter insertion in patients with extensive hepatic metastatic tumor burden Eun L. Langman,Paul V. Suhocki,Herbert I. Hurwitz,Michael A. Morse,Rebecca Burbridge,Tony P. Smith,Charles Kim	2016	6
13	A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma Elizabeth I. Buchbinder,Anasuya Gunturi,Jessica Perritt,Janice P. Dutcher,Sandra Aung,Howard L. Kaufman,Marc S. Ernstoff,Girald P. Miletello,Brendan D. Curti,Gregory A. Daniels,Sapna P. Patel,John M. Kirkwood,Sigrun Hallmeyer,Joseph I. Clark,René González,John M. Richart,Jose Lutzky,Michael A. Morse,Ryan J. Sullivan,David F. McDermott	2016	33
14	3098 Nivolumab (NIVO) monotherapy or in combination with ipilimumab (IPI) for treatment of recurrent small cell lung cancer (SCLC) Emiliano Calvo,José A. López-Martín,Johanna C. Bendell,Joseph P. Eder,Meghan M. Taylor,P.A. Ott,M. Catherine Pietanza,Leora Horn,D. Jäger,Filippo de Braud,Michael A. Morse,Paolo A. Ascierto,Denisov Le,A. Amin,Joanne Evans,Jason S. Simon,Chen‐Si Lin,O. Christensen,Scott Antonia	2015	6
15	Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes Michael K. Wong,Howard L. Kaufman,Gregory A. Daniels,David F. McDermott,Sandra Aung,James N. Lowder,Michael A. Morse	2014	4
16	Enhancement of Anti-Tumor Immunity Through Local Modulation of CTLA-4 and GITR by Dendritic Cells Scott K. Pruitt,David Boczkowski,Nicole de Rosa,Nancy Haley,Michael A. Morse,Douglas S. Tyler,Jens Dannull,Smita K. Nair	2011	1
17	Longitudinal Patterns of Chemotherapy Use in Metastatic Colorectal Cancer S. Yousuf Zafar,Jennifer Marcello,Jane L. Wheeler,Krista Rowe,Michael A. Morse,James E. Herndon,Amy P. Abernethy	2009	24
18	Update on anti-CTLA-4 antibodies in clinical trials Lee Langer,Timothy M. Clay,Michael A. Morse	2007	59
19	Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb. Michael A. Morse	2005	42
20	Liver metastases from breast cancer: Long-term survival after curative resection☆ Markus Selzner,Michael A. Morse,James J. Vredenburgh,William C. Meyers,Pierre–Alain Clavien	2000	162

About Michael A. Morse

Michael A. Morse is a scholar working on Oncology, Pathology and Forensic Medicine and Biotechnology, having authored 24 papers that have together received 2.1k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (8 papers), Colorectal Cancer Treatments and Studies (7 papers), CAR-T cell therapy research (5 papers), Genetic factors in colorectal cancer (5 papers), Pancreatic and Hepatic Oncology Research (4 papers), Cancer Treatment and Pharmacology (3 papers), Lung Cancer Research Studies (3 papers) and Immunotherapy and Immune Responses (3 papers). The work is most often cited by research in Oncology (1.8k citations), Pathology and Forensic Medicine (650 citations) and Cancer Research (365 citations). Michael A. Morse has collaborated with scholars based in United States, Belgium and France. Frequent co-authors include Michael J. Overman, Fabio Gelsomino, Ka Yeung Mark Wong, Bart Neyns, Thierry André, Sara Lonardi, Andrew Hill, Scott Kopetz, Ray McDermott and Michael B. Sawyer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact